Tumor Immune MicroEnvironment (TIME) in metastatic Renal Cell Carcinoma: Prognostic Biomarkers and Targeted Treatment Mie Wolff Kristensen Since the introduction of combination immunotherapy and TKIs, treatment outcomes for mRCC patients have improved markedly with a subset of patients achieving durable or complete responses. Despite these results, a large group of patients do not respond to treatment, and therefore, selecting the right treatment for the right patient is crucial. Treatment selection is currently based on [...]

Prostate Cancer Screening in Europe: Current Status and Future Directions By Mads Hvid Poulsen, PhD Consultant, Head of Research, Associate Professor Department for Urology, Esbjerg and Grindsted Hospital, University Hospital of Southern Denmark Department of Regional Health Research, University of Southern Denmark Prostate cancer remains the most frequently diagnosed malignancy in men across Europe, and early detection through screening has the potential to improve survival outcomes. However, the benefits of early detection must be [...]

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial Laura Iisager, Johanne Ahrenfeldt, Frede Donskov, Börje Ljungberg, Axel Bex, Lars Lund, Iben Lyskjær, Niels Fristrup. BMC Cancer. 2024 Feb 24;24(1):260. doi: 10.1186/s12885-024-11987-3. "The critical question is whether the primary kidney tumor should be removed in patients with de novo, synchronous, mRCC treated with IO-based therapy" –Niels Fristrup MD PhD, Principal Investigator the NORDIC SUN trial. Primary tumor removal by cytoreductive nephrectomy (CN) in synchronous [...]